For the readers interested in the stock health of Fate Therapeutics Inc. (FATE). It is currently valued at $84.73. When the transactions were called off in the previous session, Stock hit the highs of $88.17, after setting-off with the price of $79.69. Company’s stock value dipped to $79.305 during the trading on the day. When the trading was stopped its value was $78.90.
Recently in News on March 25, 2021, Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service. Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 years with the Company. Dr. Shoemaker has been with Fate Therapeutics since February 2009, having served as the Company’s Chief Scientific Officer since May 2015. Bob Valamehr, Ph.D., Chief Research and Development Officer of Fate Therapeutics and scientific leader of its iPSC Product Platform since January 2010, will continue to lead all research and development activities. You can read further details here
Fate Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $121.16 on 01/14/21, with the lowest value was $68.51 for the same time period, recorded on 03/29/21.
Fate Therapeutics Inc. (FATE) full year performance was 188.79%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Fate Therapeutics Inc. shares are logging -30.07% during the 52-week period from high price, and 230.98% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $25.60 and $121.16.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1280040 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Fate Therapeutics Inc. (FATE) recorded performance in the market was -6.82%, having the revenues showcasing -24.38% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 8.05B, as it employees total of 279 workers.
Market experts do have their say about Fate Therapeutics Inc. (FATE)
During the last month, 13 analysts gave the Fate Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 89.28, with a change in the price was noted +32.31. In a similar fashion, Fate Therapeutics Inc. posted a movement of +61.64% for the period of last 100 days, recording 1,162,028 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for FATE is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Fate Therapeutics Inc. (FATE)
Raw Stochastic average of Fate Therapeutics Inc. in the period of last 50 days is set at 32.68%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 60.48%. In the last 20 days, the company’s Stochastic %K was 41.12% and its Stochastic %D was recorded 34.69%.
Bearing in mind the latest performance of Fate Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -6.82%. Additionally, trading for the stock in the period of the last six months notably improved by 73.81%, alongside a boost of 188.79% for the period of the last 12 months. The shares increased approximately by 11.93% in the 7-day charts and went up by -8.67% in the period of the last 30 days. Common stock shares were lifted by -24.38% during last recorded quarter.